Incyte Corporation (INCY)
(Delayed Data from NSDQ)
$78.48 USD
-0.17 (-0.22%)
Updated Jan 22, 2020 03:57 PM ET
4-Sell 4
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 2 3 4 5 S&P |
Strong Buy Buy Hold Sell Strong Sell 500 |
24.66% 17.94% 9.57% 5.30% 2.19% 10.75% |
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
C Value | A Growth | B Momentum | A VGM
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
| Value Score | A |
|---|---|
| Growth Score | A |
| Momentum Score | A |
| VGM Score | A |
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Incyte Corporation (INCY) Quote Overview » More Research » Incyte Corporation (INCY) Full Company Report
Company Summary
Wilmington, DE-based Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland.
Incyte’s lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera (“PV”),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and ...
Company Summary
Wilmington, DE-based Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland.
Incyte’s lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera (“PV”),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. In May 2019, Jakafi obtained FDA approval for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older. While Incyte markets the drug in the United States, it is marketed by Novartis as Jakavi outside the country. Jakafi sales came in at $1.4 billion in 2018, thereby contributing 81.5% to total revenues.
The company’s second JAK1 and JAK2 inhibitor, Olumiant (baricitinib, JAK1/JAK2 inhibitor) was approved in the EU in Feb 2017 for rheumatoid arthritis (RA). Incyte is co-developing Olumiant with Eli Lilly. In June 2018, the FDA approved the 2mg dose of baricitinib as Olumiant for the treatment of adults with RA. The approval brings another source of income for Incyte as royalties.
In Jun 2016, Incyte entered into a share purchase agreement with ARIAD under which it gained the latter’s European business and the rights to Iclusig in the EU and 22 other countries including Switzerland, Norway, Turkey, Israel and Russia. Revenues for 2018 came in at $1.8 billion, up from $1.4 billion in 2017.
General Information
Incyte Corporation
1801 AUGUSTINE CUT-OFF
WILMINGTON, DE 19803
Phone: 302-498-6700
Fax: 302-425-2750
Email: mbooth@incyte.com
| Industry | Medical - Biomedical and Genetics |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 12/31/2019 |
| Next EPS Date | 2/13/2020 |
EPS Information
| Current Quarter EPS Consensus Estimate | 0.58 |
| Current Year EPS Consensus Estimate | 2.77 |
| Estimated Long-Term EPS Growth Rate | 32.00 |
| Next EPS Report Date | 2/13/2020 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 78.65 |
| 52 Week High | 96.79 |
| 52 Week Low | 72.00 |
| Beta | 0.97 |
| 20 Day Moving Average | 1,481,792.50 |
| Target Price Consensus | 89.00 |
| 4 Week | -13.98 |
| 12 Week | -5.64 |
| YTD | -9.93 |
| 4 Week | -16.50 |
| 12 Week | -13.71 |
| YTD | -10.55 |
| Shares Outstanding (millions) | 215.40 |
| Market Capitalization (millions) | 16,941.00 |
| Short Ratio | NA |
| Last Split Date | 9/1/2000 |
| Dividend Yield | 0.00% |
| Annual Dividend | $0.00 |
| Payout Ratio | 0.00 |
| Change in Payout Ratio | 0.00 |
| Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
| P/E (F1) | 23.64 |
| Trailing 12 Months | 30.37 |
| PEG Ratio | 0.74 |
| vs. Previous Year | 210.00% |
| vs. Previous Quarter | 10.71% |
| vs. Previous Year | 22.66% |
| vs. Previous Quarter | 4.09% |
| Price/Book | 6.99 |
| Price/Cash Flow | 72.17 |
| Price / Sales | 8.04 |
| 12/31/19 | NA |
| 9/30/19 | 20.07 |
| 6/30/19 | 17.10 |
| 12/31/19 | NA |
| 9/30/19 | 15.07 |
| 6/30/19 | 12.68 |
| 12/31/19 | NA |
| 9/30/19 | 5.02 |
| 6/30/19 | 5.61 |
| 12/31/19 | NA |
| 9/30/19 | 5.01 |
| 6/30/19 | 5.59 |
| 12/31/19 | NA |
| 9/30/19 | 20.67 |
| 6/30/19 | 17.18 |
| 12/31/19 | NA |
| 9/30/19 | 19.21 |
| 6/30/19 | 15.25 |
| 12/31/19 | NA |
| 9/30/19 | 20.47 |
| 6/30/19 | 15.68 |
| 12/31/19 | NA |
| 9/30/19 | 11.25 |
| 6/30/19 | 10.45 |
| 12/31/19 | NA |
| 9/30/19 | 16.32 |
| 6/30/19 | 15.51 |
| 12/31/19 | NA |
| 9/30/19 | 0.02 |
| 6/30/19 | 0.02 |
| 12/31/19 | NA |
| 9/30/19 | 2.01 |
| 6/30/19 | 2.16 |